Connect with us

Press Releases

Lubricin Data Demonstrates Significant Improvement in Multiple Signs and Symptoms of Dry Eye Disease Compared to Sodium Hyaluronate

mm

Published

on

(PRESS RELEASE) BOSTON — Lubris BioPharma announced the results of a clinical trial that showed recombinant human lubricin demonstrated significant improvement in both signs and symptoms of dry eye disease compared to sodium hyaluronate (HA). Results were published in the September issue of The Ocular Surface.

In the manuscript entitled “A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus HA 0.18% Eye Drops (Vismed) in Patients with Moderate Dry Eye Disease,” researchers evaluated the use of recombinant human lubricin, an endogenous glycoprotein with anti-inflammatory, lubricating and anti-adhesive activity as a treatment for patients with dry eye disease.

Key highlights from the study include:

  • Subjects receiving lubricin experienced greater than a 70% reduction in their symptoms from baseline;
  • Lubricin demonstrated statistically significant improvements against HA in the following symptoms: foreign body sensation (p<.013), sticky feeling (p<.0432), blurred vision (p<.0013), and photophobia (p<.011) in at least one eye;
  • Lubricin demonstrated statistically significant improvements against HA in the following objective signs of dry eye: corneal fluorescein staining (OD/OS: 43.8%, 50.0%, vs. 26.5%, 23.3%, p<.0398, p<.0232), TFBUT (p<.010), eyelid erythema (p<0.004), conjunctival erythema (p<.0013), and daily mean instillations (p<0.04), and;
  • No treatment-related, adverse events occurred during the investigation.

“Patients with dry eye suffer from a wide variety of symptoms impairing both their vision and quality of life and current treatments provide only limited symptomatic relief. These clinical results are encouraging as lubricin reduced every measured symptom, and also improved multiple objective signs of the disease. I am unaware of any other treatment that has shown such a consistent and sizable therapeutic effect, particularly when compared against another active compound,” said Edward Truitt, a co-author of the study and CEO of Lubris BioPharma.  “We are looking forward to the next stage of clinical development.”

rh-Lubricin is the recombinant form of Lubricin (PRG4), a large endogenous complex glycoprotein that binds to, and protects tissue surfaces from friction induced wear & damage. Lubricin is the most lubricating and anti-adhesive molecule in the human body and has natural anti-inflammatory properties as well. Originally identified in joints, lubricin is also found on the ocular surface and in numerous additional tissues throughout the human body.

ABSTRACT LINK: http://www.ncbi.nlm.nih.gov/pubmed/27614318

Advertisement

ARTICLE REFERENCE: The Ocular Surface. August 2016, ahead of print. DOI: http://dx.doi.org/10.1016/j.jtos.2016.08.004.

 

SPONSORED VIDEO

Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular

Link partner: indobet autowin88 vegasslot77 mantra88 ligasedayu warungtoto login sbobet vegas4d indobet ingatbola88 ligaplay dewagg hoki368 qqnusa ligagg zeus138 bro138 bos88 ligaciputra